Lucid Diagnostics Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Lucid Diagnostics Inc. (LUCD) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.33 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- Lucid Diagnostics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.35, a 8.16% decline year-over-year.
- Lucid Diagnostics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.47, a 17.60% increase year-over-year.
- Lucid Diagnostics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.25.
- Lucid Diagnostics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $4.16.
- Lucid Diagnostics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.35, a 11.57% increase from fiscal 2024.
- Lucid Diagnostics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.21, a 8.33% decline from fiscal 2023.
- Lucid Diagnostics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.32, a 64.13% decline from fiscal 2022.
- Lucid Diagnostics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $3.68, a 59.47% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.33 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $1.35 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $1.35 10-K · filed 2026-03-25 | |||
| 2025-09-30 | $1.42 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $1.46 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $1.47 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $1.21 10-K · filed 2026-03-25 | |||
| 2024-09-30 | $1.22 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $1.23 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $1.25 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $1.32 10-K · filed 2025-03-24 | |||
| 2023-09-30 | $1.32 10-Q · filed 2023-11-13 | |||
| 2022-12-31 | $3.68 10-K · filed 2024-03-25 | |||
| 2022-06-30 | $3.82 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $4.16 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $9.08 10-K · filed 2022-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Apyx Medical Corp (APYX) | United States | $0.120B | -21.85 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |